Contact
QR code for the current URL

Story Box-ID: 971123

Xenios AG Im Zukunftspark 1 74076 Heilbronn, Germany http://www.xenios-ag.com
Contact Ms Sandra Hubatschek +49 7131 2706388
Company logo of Xenios AG

Merger: Novalung becomes fully integrated within Xenios

(PresseBox) (Heilbronn, )
Novalung GmbH, which specialises in solutions for respiratory failure, was absorbed into Xenios AG on 30 August 2019. Processes will be streamlined as a result and the company will become more closely aligned with the parent company Fresenius Medical Care.

Novalung was established in 2003 and specialises in the treatment of respiratory failure. The company has been part of Xenios AG since 2013.

Since the end of 2016, Xenios has been part of Fresenius Medical Care, the leading provider of products and services for people with kidney diseases. “This merger will produce more streamlined processes within Xenios and can in turn impact positively on our response times to customer enquiries and orders,” explains Dr. Andreas Terpin, CEO of Xenios AG. “At the same time we are putting in place the conditions for the ongoing integration of our products and therapies within the parent company Fresenius Medical Care.”

While expansion of the product portfolio is ongoing, proven elements will remain under the umbrella of Xenios. “Novalung” will be retained as an established brand in the intensive care market and developed further with the support of the parent company. Novalung is to serve in future as a key pillar in the area of multi-organ support within the Fresenius Medical Care concept.

“Xenios will continue to offer and produce the Novalung product and therapy portfolio related to lung support. Only the name of the legal manufacturer on the product packaging will change. All existing contact persons remain and will continue to guarantee high quality in order processing,” commented Dr. Jürgen Böhm, Chief Medical Officer of Xenios.

The merger was notarized and entered in the commercial register in mid-August.

Website Promotion

Website Promotion
Xenios - a Fresenius Medical Care company

Xenios AG

Xenios AG - a company of the Fresenius Medical Care Group - is a pioneer in extracorporeal heart and lung support. The Novalung and Medos products offer a wide range of heart and lung support products via a single platform, the Xenios console.

Xenios mission is to improve patient well-being and care. The Novalung therapy aims at a paradigm shift in lung support: enabling the treatment of patients that are awake, self-determined and mobile.

Xenios AG has been part of Fresenius Medical Care, the world's leading provider of products and services for people with kidney disease since the end of 2016. Xenios complements the group's portfolio in the area of holistic multi-organ support of FME.

Visit the new website of Xenios AG:

www.xenios-ag.com

The publisher indicated in each case (see company info by clicking on image/title or company info in the right-hand column) is solely responsible for the stories above, the event or job offer shown and for the image and audio material displayed. As a rule, the publisher is also the author of the texts and the attached image, audio and information material. The use of information published here is generally free of charge for personal information and editorial processing. Please clarify any copyright issues with the stated publisher before further use. In case of publication, please send a specimen copy to service@pressebox.de.
Important note:

Systematic data storage as well as the use of even parts of this database are only permitted with the written consent of unn | UNITED NEWS NETWORK GmbH.

unn | UNITED NEWS NETWORK GmbH 2002–2024, All rights reserved

The publisher indicated in each case (see company info by clicking on image/title or company info in the right-hand column) is solely responsible for the stories above, the event or job offer shown and for the image and audio material displayed. As a rule, the publisher is also the author of the texts and the attached image, audio and information material. The use of information published here is generally free of charge for personal information and editorial processing. Please clarify any copyright issues with the stated publisher before further use. In case of publication, please send a specimen copy to service@pressebox.de.